Exchange: NASDAQ·Updated 03:59 PM EDT

About ANABV

About

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in the development of antibody product candidates. The firm’s product pipeline includes ANB030, ANB030, and Imsidolimab. It also offers the SHM platform that replicates the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A

Frequently Asked Questions

Advertisement|Remove ads.